La Jolla Pharmaceutical Company CEO Buys $76,240 in Stock (LJPC)

Share on StockTwits

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George Tidmarsh purchased 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $9.53 per share, for a total transaction of $76,240.00. Following the completion of the purchase, the chief executive officer now directly owns 1,391,086 shares in the company, valued at approximately $13,257,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

LJPC has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of La Jolla Pharmaceutical Company from $32.00 to $33.00 in a research note on Monday, April 7th. Separately, analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $16.00 to $34.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Finally, analysts at Chardan Capital raised their price target on shares of La Jolla Pharmaceutical Company to $54.00 in a research note on Tuesday, March 11th. They now have a “positive” rating on the stock.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at 9.09 on Wednesday. La Jolla Pharmaceutical Company has a 52-week low of $0.16 and a 52-week high of $19.50. The stock has a 50-day moving average of $11.00 and a 200-day moving average of $8.86. The company’s market cap is $66.0 million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.24) by $0.17. On average, analysts predict that La Jolla Pharmaceutical Company will post $-2.82 earnings per share for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Insider Selling: Zulily Insider Sells 50,000 Shares of Stock
Insider Selling: Zulily Insider Sells 50,000 Shares of Stock
Ralph Lauren Corp major shareholder Sells $8,253,000 in Stock
Ralph Lauren Corp major shareholder Sells $8,253,000 in Stock
Insider Selling: Clean Energy Fuels Corp CFO Sells 160,444 Shares of Stock
Insider Selling: Clean Energy Fuels Corp CFO Sells 160,444 Shares of Stock
Silver Bull Resources major shareholder Lazarus Investment Partners Ll Acquires 138,261 Shares
Silver Bull Resources major shareholder Lazarus Investment Partners Ll Acquires 138,261 Shares
PTC Therapeutics Insider Mark Rothera Sells 16,000 Shares
PTC Therapeutics Insider Mark Rothera Sells 16,000 Shares
Jazz Pharmaceuticals plc – Director Seamus Mulligan Sells 50,000 Shares
Jazz Pharmaceuticals plc – Director Seamus Mulligan Sells 50,000 Shares


Leave a Reply

 
© 2006-2014 Mideast Time.